The Alzheimer's Drug Discovery Foundation (ADDF) has
been a source of several peer-reviewed grants supporting PTX technology and its
peer-reviewed Biotechnology Program maintains scientific oversight and an equity
position in PTX.

The Alzheimer's Association  Part the Cloud Program has provided peer-reviewed funding in support of the successful completion of the PTX LM11A-31 phase 1 safety trial.

In 2016 PharmatrophiX was awarded a peer-reviewed NIH/National Institute of Aging Alzheimer’s Disease Pilot Clinical Trial Award to provide support for its current phase 2a exploratory endpoint trial. In 2018, additional funding was provided to expand subject enrollment and testing. The principal investigator is Dr. Manfred Windisch, CEO and President, NeuroScios, a PharmatrophiX partner and the co-investigators are Drs. Maria Eriksdotter and Agneta Nordberg at the Karolinska Institute in Stockholm.